Trial · NCT00452023
Pegasys® in Patients With Myeloproliferative Diseases
NCT00452023, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2024-12-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pegasys® in Patients With Myeloproliferative Diseases. Trials, record NCT00452023. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00452023
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pegasys® in Patients With Myeloproliferative Diseases
- NCT number
- NCT00452023
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 83 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Myeloproliferative Disorders
- Interventions
- IFN-alpha2a
- First posted
- 2007-03-26
- Last updated
- 2024-12-11
- Results first posted
- 2024-12-11
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Complete Response (CR) or Partial Response (PR) | Up to 18 years | CR = Reduction of PLT to \<440x109/l and disappearance of thromboembolic events, without the use of anagrelide or hydroxyurea PR = Reduction of PLT by 50% but still \>440x109/l or reduction of thromboembolic events by 50%, without the use of anagrelide or hydroxyurea |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Complete Response (CR) or Partial Response (PR) | Up to 18 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Complete Response (CR) or Partial Response (PR) | IFN-alpha2a 450 Microgram (mcg) | 3 | Participants | ||
| Number of Patients With Complete Response (CR) or Partial Response (PR) | IFN-alpha2a 360 Microgram (mcg) | 3 | Participants | ||
| Number of Patients With Complete Response (CR) or Partial Response (PR) | IFN-alpha2a 270 Microgram (mcg) | 14 | Participants | ||
| Number of Patients With Complete Response (CR) or Partial Response (PR) | IFN-alpha2a 180 Microgram (mcg) | 23 | Participants | ||
| Number of Patients With Complete Response (CR) or Partial Response (PR) | IFN-alpha2a 90 Microgram (mcg) | 23 | Participants |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | IFN-alpha2a 450 Microgram (mcg) Injection | 3 | |
| Overall Study | STARTED | IFN-alpha2a 360 Microgram (mcg) Injection | 3 | |
| Overall Study | STARTED | IFN-alpha2a 270 Microgram (mcg) Injection | 19 | |
| Overall Study | STARTED | IFN-alpha2a 180 Microgram (mcg) Injection | 26 | |
| Overall Study | STARTED | IFN-alpha2a 90 Microgram (mcg) Injection | 32 | |
| Overall Study | COMPLETED | IFN-alpha2a 450 Microgram (mcg) Injection | 3 | |
| Overall Study | COMPLETED | IFN-alpha2a 360 Microgram (mcg) Injection | 3 | |
| Overall Study | COMPLETED | IFN-alpha2a 270 Microgram (mcg) Injection | 19 | |
| Overall Study | COMPLETED | IFN-alpha2a 180 Microgram (mcg) Injection | 26 | |
| Overall Study | COMPLETED | IFN-alpha2a 90 Microgram (mcg) Injection | 32 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events155
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | IFN-alpha2a 450 Microgram (mcg) | 0 | 3 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | IFN-alpha2a 360 Microgram (mcg) | 3 | 3 | 3 |
| other | Neutropenia | Blood and lymphatic system disorders | IFN-alpha2a 270 Microgram (mcg) | 6 | 19 | 6 |
| other | Neutropenia | Blood and lymphatic system disorders | IFN-alpha2a 180 Microgram (mcg) | 4 | 26 | 4 |
| other | Neutropenia | Blood and lymphatic system disorders | IFN-alpha2a 90 Microgram (mcg) | 2 | 32 | 2 |
| other | Elevated transaminase | Investigations | IFN-alpha2a 450 Microgram (mcg) | 2 | 3 | 2 |
| other | Elevated transaminase | Investigations | IFN-alpha2a 360 Microgram (mcg) | 1 | 3 | 1 |
| other | Elevated transaminase | Investigations | IFN-alpha2a 270 Microgram (mcg) | 1 | 19 | 2 |
| other | Elevated transaminase | Investigations | IFN-alpha2a 180 Microgram (mcg) | 1 | 26 | 1 |
| other | Elevated transaminase | Investigations | IFN-alpha2a 90 Microgram (mcg) | 2 | 32 | 2 |
1 to 10 of 155Source ClinicalTrials.gov
See all 155 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | IFN-alpha2a 450 Microgram (mcg) | 0 | 3 |
| Total, all-cause mortality | IFN-alpha2a 360 Microgram (mcg) | 0 | 3 |
| Total, all-cause mortality | IFN-alpha2a 270 Microgram (mcg) | 0 | 19 |
| Total, all-cause mortality | IFN-alpha2a 180 Microgram (mcg) | 2 | 26 |
| Total, all-cause mortality | IFN-alpha2a 90 Microgram (mcg) | 1 | 32 |
| Total, other adverse events | IFN-alpha2a 450 Microgram (mcg) | 2 | 3 |
| Total, other adverse events | IFN-alpha2a 360 Microgram (mcg) | 3 | 3 |
| Total, other adverse events | IFN-alpha2a 270 Microgram (mcg) | 9 | 19 |
| Total, other adverse events | IFN-alpha2a 180 Microgram (mcg) | 8 | 26 |
| Total, other adverse events | IFN-alpha2a 90 Microgram (mcg) | 7 | 32 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00452023
GET https://conductscience.org/api/trials/v1/NCT00452023/events?page=2